خدمة تلخيص النصوص العربية أونلاين،قم بتلخيص نصوصك بضغطة واحدة من خلال هذه الخدمة
In January, an expert advisory panel of the FDA debated whether florbetapir was
ready for marketing. The group did not suggest that the FDA approve the drug at
this time. Still, the experts said they made the judgment based on available
information. And they asked for more information. They also set conditions for
accepting florbetapir.
One condition is for the manufacturer to show evidence that florbetapir correctly
identifies plaques. The other condition is that the manufacturer prepare a training
program for experts in nuclear medicine. The advisory panel said the doctors reading
the test need additional education to correctly identify the plaques.
The Food and Drug Administration will decide next month whether to accept the
panel’s suggestions. The FDA normally follows the advice of its expert advisers, but
not always.
If it is approved, florbetapir would be the first agent permitted to measure plaque
deposits in living patients. Still, the presence of plaques does not prove that a patient
has Alzheimer’s disease. Doctors say some people with amyloid plaques in their
brains do not have the condition.
An estimated thirty million people around the world have Alzheimer’s disease. In
the United States alone, more than five million people suffer from this presently
incurable brain disorder.
Alzheimer’s affects memory and personality -- those qualities that make a person an
individual. At first, people with the condition forget simple things, like where they
left the keys to their car. But as time passes, they forget more and more. They may
forget what a key is used for.
Patients forget the names of their husbands, wives or children. Then they forget who
they are.
Finally, they remember almost nothing. It is as if their brains die before the other
parts of the body. Victims of Alzheimer’s do die from its effects or conditions linked
to it. But death may not come for many years.
Dementia is the loss of thinking ability that is severe enough to interfere with daily
activities. It is not a disease itself. Instead, dementia is a group of signs of some
conditions and diseases.
In January, an expert advisory panel of the FDA debated whether florbetapir was
ready for marketing. The group did not suggest that the FDA approve the drug at
this time. Still, the experts said they made the judgment based on available
information. And they asked for more information. They also set conditions for
accepting florbetapir.
One condition is for the manufacturer to show evidence that florbetapir correctly
identifies plaques. The other condition is that the manufacturer prepare a training
program for experts in nuclear medicine. The advisory panel said the doctors reading
the test need additional education to correctly identify the plaques.
The Food and Drug Administration will decide next month whether to accept the
panel’s suggestions. The FDA normally follows the advice of its expert advisers, but
not always.
If it is approved, florbetapir would be the first agent permitted to measure plaque
deposits in living patients. Still, the presence of plaques does not prove that a patient
has Alzheimer’s disease. Doctors say some people with amyloid plaques in their
brains do not have the condition.
An estimated thirty million people around the world have Alzheimer’s disease. In
the United States alone, more than five million people suffer from this presently
incurable brain disorder.
Alzheimer’s affects memory and personality -- those qualities that make a person an
individual. At first, people with the condition forget simple things, like where they
left the keys to their car. But as time passes, they forget more and more. They may
forget what a key is used for.
Patients forget the names of their husbands, wives or children. Then they forget who
they are.
Finally, they remember almost nothing. It is as if their brains die before the other
parts of the body. Victims of Alzheimer’s do die from its effects or conditions linked
to it. But death may not come for many years.
Dementia is the loss of thinking ability that is severe enough to interfere with daily
activities. It is not a disease itself. Instead, dementia is a group of signs of some
conditions and diseases.
تلخيص النصوص العربية والإنجليزية اليا باستخدام الخوارزميات الإحصائية وترتيب وأهمية الجمل في النص
يمكنك تحميل ناتج التلخيص بأكثر من صيغة متوفرة مثل PDF أو ملفات Word أو حتي نصوص عادية
يمكنك مشاركة رابط التلخيص بسهولة حيث يحتفظ الموقع بالتلخيص لإمكانية الإطلاع عليه في أي وقت ومن أي جهاز ماعدا الملخصات الخاصة
نعمل علي العديد من الإضافات والمميزات لتسهيل عملية التلخيص وتحسينها
Deloitte's CFO Insights highlights the evolving employee-work relationship and suggests that firms s...
المرشح الحيوي ( البيولوجي) Triklingfilter صمم أول مرشح حيوي في بريطانيا سنة ۱۸۹۳ كطريقة مشابهة لاست...
مقدمة: في عالم الأعمال الديناميكي اليوم، يصبح التشخيص الاستراتيجي ضرورة حتمية لضمان بقاء المؤسسات و...
the Continents. He showed us how the South America and Africa contain fossils of animals like mesos...
المملكة المغربية 2022/06/08 بتاريخ أصدرت المحكمة الابتدائية الزجرية بالدار البيضاء في جلستها العلن...
نهر النيل: ويدخل نهر النيل األ ارضي المصرية قادماًمن الجنوب، عند قرية أدندان على الحدود المصرية السو...
فنيا تتم عملية التصوير التلفزيوني عندما تعكس عدسة الكاميرا المنظر الذي أمامها على لوحة حساسة داخل صم...
يعتبر الجهاز المصرفي من الأجهزة التي تلعب دورا أساسيا في تخطيط وتنفيذ السياسات المالية والاقتصادية، ...
Genotype–phenotype correlation of nonsynonymous mutations with serum iron and hepcidin levels in IDA...
التجربة الشعرية لنزار قباني كان خروج نزار إلى ساحة الشعر صاخبا، عبر نشر ديوانه "قالت لي السمراء" عام...
هكذا آمن )مراد( طوال عمره.. لذا فقد خفّت حدّة االندهاش لديه وحلّلألشياء مقدمات تؤدي إىل اخلواتيم حمل...
إن الرافد القوي الذي أثر في شخصية عثمان ورا وصقل مواهبه وفجر طاقته، وهذب نفسه هو مصاحبته لرسول الله ...